Transforming healthcare sustainably

Life-changing innovation is only meaningful if it reaches those who need it. We put access at the core of our business and consider it a key part of our commitment to improving patient outcomes. We partner with stakeholders at global, country and community levels to enable access to innovative healthcare, no matter where people live.

“It has been a great honour for me to work for this unique and excellent company. With Severin Schwan and Thomas Schinecker, Roche is being led into the future by a strong and highly experienced team.”

Dr Christoph Franz

Read the Chairman’s letter to shareholders
“There is no doubt that, throughout his tenure, our outgoing Chairman has strongly influenced Roche’s strategic development. Thank you very much, Christoph Franz!”

André Hoffmann

Read the Vice-Chairman’s letter
“The development and delivery of pioneering medicines and diagnostics is at the heart of our mission. I am particularly pleased that we brought two new medicines to patients: for certain severe eye diseases and for a form of blood cancer.”

Dr Severin Schwan

Read the CEO’s letter to shareholders


Roche Group sales:
CHF 63.3 billion


Pharmaceuticals Division sales:
CHF 45.6 billion


Diagnostics Division sales:
CHF 17.7 billion


Core investments in
research and development:
CHF 14.1 billion


Core operating profit:
CHF 22.2 billion


Dividend proposal:
CHF 9.50

*Unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates (CER; average rates 2021) and all total figures quoted are reported in CHF.

United States


  • Actemra/RoActemra (two indications)

  • Cotellic

  • Lunsumio

  • Tecentriq

  • Evrysdi

  • Vabysmo (two indications)

  • Xofluza



  • Lunsumio

  • Polivy

  • Tecentriq

  • Vabysmo (two indications)



  • Actemra/RoActemra

  • Rozlytrek (two indications)

  • Tecentriq

Japan – Chugai


  • Actemra/RoActemra

  • Gazyva/Gazyvaro

  • Hemlibra

  • Perjeta + Herceptin

  • Polivy

  • Tecentriq

  • MabThera/Rituxan

  • Vabysmo (two indications)

Molecular Lab

  • 2 new platforms

  • 2 new tests

  • 1 other

Pathology Lab

  • 1 new platform

  • 9 new tests

  • 3 new digital solutions

  • 1 other

Core Lab

  • 4 new platforms

  • 12 new tests

  • 1 new digital solution

Point of Care

  • 1 new test

Diabetes Care

  • 1 new digital solution

Roche Information Solutions

  • 4 new digital solutions

>3.2 million

people were on Roche patient support programmes, a 14% increase from 2021

Ranked 10th

worldwide in the Access to Medicine Index

>8 million

HIV-positive patients were able to have their viral load monitored through the Global Access Program to check for treatment efficacy

13 cities

We continue to work with City Cancer Challenge, who are active in 13 cities worldwide reaching an estimated 59.6 million people

100,000 people

will be screened for diabetes over the next two years in Meru, Kenya, through the Mwanga access project

29 billion

tests conducted with Roche Diagnostics products


women in executive positions


under-represented nationalities in executive positions*


diversity networks and chapters around the globe

4 strategic D&I pillars

Global D&I strategy focuses on four pillars: patient, people, culture, and society

No significant difference

in pay between men and women in similar jobs as our organisation-wide analysis confirmed

Roche CEO signs pledge

with the Valuable 500 committing support for disability inclusion.

*Includes individuals from countries in Asia, Latin America, Eastern Europe, Middle East and Africa

Key highlights

Discover how Roche made an impact in 2022

Uncover insights into our purpose-led journey focused on life-changing innovation, and see how our efforts to improve access to healthcare impacted millions of patients around the world.


Download Annual Report

Download Finance Report

Investor updates

Join us!

Learn more about exciting career opportunities at Roche, one of the world’s leading research-based healthcare companies.

Latest media releases